{
    "clinical_study": {
        "@rank": "63869", 
        "acronym": "N2011-01", 
        "arm_group": [
            {
                "arm_group_label": "Single-Agent 131I-MIBG", 
                "arm_group_type": "Active Comparator", 
                "description": "Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15."
            }, 
            {
                "arm_group_label": "131I-MIBG with Vincristine/Irinotecan", 
                "arm_group_type": "Active Comparator", 
                "description": "Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0;  irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4.  Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6.  31I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15."
            }, 
            {
                "arm_group_label": "131I-MIBG with Vorinostat", 
                "arm_group_type": "Active Comparator", 
                "description": "Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses).  131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)\n      and compare their effects on tumor response and associated side effects, to determine if one\n      therapy is better than the other for people diagnosed with relapsed or persistent\n      neuroblastoma."
        }, 
        "brief_title": "131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat", 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be > 24 months and < 30 years of age when registered on study.\n\n          -  Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less\n             than a partial response to standard treatment or persistent neuroblastoma that had at\n             least a partial response to frontline therapy frontline therapy with > 3 residual\n             lesions on end-induction MIBG scan.\n\n          -  Patients must have evidence of MIBG uptake into tumor at \u2265 one site within 4 weeks\n             prior to entry on study and subsequent to any intervening therapy.\n\n          -  Patients must have adequate heart, kidney, liver and bone marrow function.  Patients\n             who have bone marrow disease must still have adequate bone marrow function to enter\n             the study.\n\n          -  Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable\n             CD34+ cells/kg available.\n\n        Exclusion Criteria:\n\n          -  They have had previous I-131 MIBG therapy\n\n          -  They have other medical problems that could get much worse with this treatment.\n\n          -  They are pregnant or breast feeding.\n\n          -  They have a history of a venous or arterial thrombosis that was not associated to a\n             central line.\n\n          -  They have active infections such as hepatitis or fungal infections.\n\n          -  They have active diarhhea.\n\n          -  They have had an  allogeneic stem cell transplant (received stem cell from someone\n             else)\n\n          -  They can't cooperate with the special precautions that are needed for this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035137", 
            "org_study_id": "N2011-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single-Agent 131I-MIBG", 
                    "131I-MIBG with Vincristine/Irinotecan", 
                    "131I-MIBG with Vorinostat"
                ], 
                "intervention_name": "131I-MIBG", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "131I-Metaiodobenzylguanidine", 
                    "Iobenguane sulfate", 
                    "m-Iodobenzylguanidine sulfate", 
                    "MIBG"
                ]
            }, 
            {
                "arm_group_label": "131I-MIBG with Vincristine/Irinotecan", 
                "intervention_name": "Vincristine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "131I-MIBG with Vincristine/Irinotecan", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "131I-MIBG with Vorinostat", 
                "intervention_name": "Vorinostat", 
                "intervention_type": "Drug", 
                "other_name": "Zolinza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vincristine", 
                "Irinotecan", 
                "Vorinostat", 
                "3-Iodobenzylguanidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027-0700"
                    }, 
                    "name": "Childrens Hospital Los Angeles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Lucile Salter Packer Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "UCSF Helen Diller Family Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Children Hospital of Colorado"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago, Comer Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Children's Hospital Boston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "C.S Mott Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4318"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Cook Children's Healthcare System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Seattle Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G1X8"
                    }, 
                    "name": "Hospital for Sick Children"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With VOrinostat for Resistant/Relapsed Neuroblastoma", 
        "overall_contact": {
            "email": "nantops@chla.usc.edu", 
            "last_name": "Araz Marachelian, MD", 
            "phone": "323-361-5687"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Steven DuBois, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To identify the MIBG treatment regimen associated with the highest overall response rate after one course of treatment on the following three arms: single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.", 
            "measure": "Objective tumor response", 
            "safety_issue": "No", 
            "time_frame": "43-50 days from study day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare toxicity profiles associated with occurence of delayed engraftment defined as failure to achieve ANC >= 500/uL by day 43 and platelet count >= 20,000 by day 71 of protocol therapy in absence of progressive bone marrow metastatic disease for each of the following 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.", 
                "measure": "Delayed engraftment", 
                "safety_issue": "Yes", 
                "time_frame": "43-71 days after study day 1."
            }, 
            {
                "description": "To compare the occurence of toxic deaths for each of the following 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.", 
                "measure": "Occurence of toxic death", 
                "safety_issue": "Yes", 
                "time_frame": "Days 43 to 50 after study day 1"
            }, 
            {
                "description": "Compare toxicity profiles for grade 3 or greater toxicities associated with each of 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG", 
                "measure": "Grade 3 or greater non-hematologic toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "day 43 - 50 after study day 1"
            }
        ], 
        "source": "New Approaches to Neuroblastoma Therapy Consortium", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New Approaches to Neuroblastoma Therapy Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}